HUMAN IMMUNODEFICIENCY VIRUS INACTIVATOR
To provide a human immunodeficiency virus (HIV) inactivator that has high safety and also has HIV inactivating effect.SOLUTION: An HIV inactivator contains a lignin component at least containing a lignin derivative as an active ingredient. The mass ratio of the extraction component content to the me...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | AIMI HIKARU SAKAGAMI HIROSHI ASAI DAISUKE SHINDO DAIKI FUKUCHI KUNIHIKO |
| description | To provide a human immunodeficiency virus (HIV) inactivator that has high safety and also has HIV inactivating effect.SOLUTION: An HIV inactivator contains a lignin component at least containing a lignin derivative as an active ingredient. The mass ratio of the extraction component content to the methoxyl group content is 0.0001-0.5 in terms of the solid content of the lignin component. The lignin derivative preferably at least contains ligninsulfonic acid. The methoxyl group content and the extraction component content are preferably 2.0 mass% or more and 1.7 mass% or less, respectively, in terms of the solid content of the lignin component.SELECTED DRAWING: None
【課題】本発明の課題は、安全性が高く、かつヒト免疫不全ウイルス（ＨＩＶ）不活性化効果を有するＨＩＶ不活性化剤を提供することにある。【解決手段】本発明は、リグニン誘導体を少なくとも含むリグニン成分を有効成分とし、リグニン成分の固形分当たりの、抽出成分量のメトキシル基量に対する質量比が０．０００１～０．５である、ＨＩＶ不活性化剤を提供する。リグニン誘導体は、リグニンスルホン酸を少なくとも含むことが好ましい。リグニン成分の固形分当たりのメトキシル基量、リグニン成分の固形分当たりの抽出成分量は、それぞれ２．０質量％以上、１．７質量％以下が好ましい。【選択図】なし |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2022163295A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2022163295A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2022163295A3</originalsourceid><addsrcrecordid>eNrjZNDwCPV19FPw9PUN9fN3cXXzdPZ09XOOVAjzDAoNVvD0c3QO8QxzDPEP4mFgTUvMKU7lhdLcDEpuriHOHrqpBfnxqcUFicmpeakl8V4BRgZGRoZmxkaWpo7GRCkCAHPHJOE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>HUMAN IMMUNODEFICIENCY VIRUS INACTIVATOR</title><source>esp@cenet</source><creator>AIMI HIKARU ; SAKAGAMI HIROSHI ; ASAI DAISUKE ; SHINDO DAIKI ; FUKUCHI KUNIHIKO</creator><creatorcontrib>AIMI HIKARU ; SAKAGAMI HIROSHI ; ASAI DAISUKE ; SHINDO DAIKI ; FUKUCHI KUNIHIKO</creatorcontrib><description>To provide a human immunodeficiency virus (HIV) inactivator that has high safety and also has HIV inactivating effect.SOLUTION: An HIV inactivator contains a lignin component at least containing a lignin derivative as an active ingredient. The mass ratio of the extraction component content to the methoxyl group content is 0.0001-0.5 in terms of the solid content of the lignin component. The lignin derivative preferably at least contains ligninsulfonic acid. The methoxyl group content and the extraction component content are preferably 2.0 mass% or more and 1.7 mass% or less, respectively, in terms of the solid content of the lignin component.SELECTED DRAWING: None
【課題】本発明の課題は、安全性が高く、かつヒト免疫不全ウイルス（ＨＩＶ）不活性化効果を有するＨＩＶ不活性化剤を提供することにある。【解決手段】本発明は、リグニン誘導体を少なくとも含むリグニン成分を有効成分とし、リグニン成分の固形分当たりの、抽出成分量のメトキシル基量に対する質量比が０．０００１～０．５である、ＨＩＶ不活性化剤を提供する。リグニン誘導体は、リグニンスルホン酸を少なくとも含むことが好ましい。リグニン成分の固形分当たりのメトキシル基量、リグニン成分の固形分当たりの抽出成分量は、それぞれ２．０質量％以上、１．７質量％以下が好ましい。【選択図】なし</description><language>eng ; jpn</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221026&DB=EPODOC&CC=JP&NR=2022163295A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221026&DB=EPODOC&CC=JP&NR=2022163295A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>AIMI HIKARU</creatorcontrib><creatorcontrib>SAKAGAMI HIROSHI</creatorcontrib><creatorcontrib>ASAI DAISUKE</creatorcontrib><creatorcontrib>SHINDO DAIKI</creatorcontrib><creatorcontrib>FUKUCHI KUNIHIKO</creatorcontrib><title>HUMAN IMMUNODEFICIENCY VIRUS INACTIVATOR</title><description>To provide a human immunodeficiency virus (HIV) inactivator that has high safety and also has HIV inactivating effect.SOLUTION: An HIV inactivator contains a lignin component at least containing a lignin derivative as an active ingredient. The mass ratio of the extraction component content to the methoxyl group content is 0.0001-0.5 in terms of the solid content of the lignin component. The lignin derivative preferably at least contains ligninsulfonic acid. The methoxyl group content and the extraction component content are preferably 2.0 mass% or more and 1.7 mass% or less, respectively, in terms of the solid content of the lignin component.SELECTED DRAWING: None
【課題】本発明の課題は、安全性が高く、かつヒト免疫不全ウイルス（ＨＩＶ）不活性化効果を有するＨＩＶ不活性化剤を提供することにある。【解決手段】本発明は、リグニン誘導体を少なくとも含むリグニン成分を有効成分とし、リグニン成分の固形分当たりの、抽出成分量のメトキシル基量に対する質量比が０．０００１～０．５である、ＨＩＶ不活性化剤を提供する。リグニン誘導体は、リグニンスルホン酸を少なくとも含むことが好ましい。リグニン成分の固形分当たりのメトキシル基量、リグニン成分の固形分当たりの抽出成分量は、それぞれ２．０質量％以上、１．７質量％以下が好ましい。【選択図】なし</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNDwCPV19FPw9PUN9fN3cXXzdPZ09XOOVAjzDAoNVvD0c3QO8QxzDPEP4mFgTUvMKU7lhdLcDEpuriHOHrqpBfnxqcUFicmpeakl8V4BRgZGRoZmxkaWpo7GRCkCAHPHJOE</recordid><startdate>20221026</startdate><enddate>20221026</enddate><creator>AIMI HIKARU</creator><creator>SAKAGAMI HIROSHI</creator><creator>ASAI DAISUKE</creator><creator>SHINDO DAIKI</creator><creator>FUKUCHI KUNIHIKO</creator><scope>EVB</scope></search><sort><creationdate>20221026</creationdate><title>HUMAN IMMUNODEFICIENCY VIRUS INACTIVATOR</title><author>AIMI HIKARU ; SAKAGAMI HIROSHI ; ASAI DAISUKE ; SHINDO DAIKI ; FUKUCHI KUNIHIKO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2022163295A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; jpn</language><creationdate>2022</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>AIMI HIKARU</creatorcontrib><creatorcontrib>SAKAGAMI HIROSHI</creatorcontrib><creatorcontrib>ASAI DAISUKE</creatorcontrib><creatorcontrib>SHINDO DAIKI</creatorcontrib><creatorcontrib>FUKUCHI KUNIHIKO</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>AIMI HIKARU</au><au>SAKAGAMI HIROSHI</au><au>ASAI DAISUKE</au><au>SHINDO DAIKI</au><au>FUKUCHI KUNIHIKO</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>HUMAN IMMUNODEFICIENCY VIRUS INACTIVATOR</title><date>2022-10-26</date><risdate>2022</risdate><abstract>To provide a human immunodeficiency virus (HIV) inactivator that has high safety and also has HIV inactivating effect.SOLUTION: An HIV inactivator contains a lignin component at least containing a lignin derivative as an active ingredient. The mass ratio of the extraction component content to the methoxyl group content is 0.0001-0.5 in terms of the solid content of the lignin component. The lignin derivative preferably at least contains ligninsulfonic acid. The methoxyl group content and the extraction component content are preferably 2.0 mass% or more and 1.7 mass% or less, respectively, in terms of the solid content of the lignin component.SELECTED DRAWING: None
【課題】本発明の課題は、安全性が高く、かつヒト免疫不全ウイルス（ＨＩＶ）不活性化効果を有するＨＩＶ不活性化剤を提供することにある。【解決手段】本発明は、リグニン誘導体を少なくとも含むリグニン成分を有効成分とし、リグニン成分の固形分当たりの、抽出成分量のメトキシル基量に対する質量比が０．０００１～０．５である、ＨＩＶ不活性化剤を提供する。リグニン誘導体は、リグニンスルホン酸を少なくとも含むことが好ましい。リグニン成分の固形分当たりのメトキシル基量、リグニン成分の固形分当たりの抽出成分量は、それぞれ２．０質量％以上、１．７質量％以下が好ましい。【選択図】なし</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; jpn |
| recordid | cdi_epo_espacenet_JP2022163295A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | HUMAN IMMUNODEFICIENCY VIRUS INACTIVATOR |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T19%3A27%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=AIMI%20HIKARU&rft.date=2022-10-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2022163295A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |